Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple mineral ease severe asthma attacks in kids?

NCT ID NCT06785272

Symptom relief Sponsor: Suzanne Schuh Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether giving intravenous magnesium (IVMg) early to children aged 2-17 with severe asthma in the emergency room can reduce their breathing distress more than a placebo. About 192 children who still have moderate-to-severe symptoms after initial treatment will receive either IVMg or a placebo. The goal is to see if magnesium helps them breathe easier within two hours, potentially improving care and reducing hospital stays.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 192 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

2 to 17 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: 1. Age 2.00-17.99 years (prior to 18th birthday), 2. Diagnosis of asthma, defined as an asthma or probable asthma diagnosis/asthma-like phenotype made by a physician (this includes ED physician) in a patient who in the opinion of the treating ED physician requires therapy for acute asthma in the ED (GINA asthma guidelines, 2024). 3. Moderate-severe asthma after initial therapy with 3 treatments of inhaled salbutamol and ipratropium, defined as an eligibility PRAM ≥5, indicating a strong association with hospitalization. Exclusion criteria: 1. Receipt of IVMg within 24 hours prior to ED arrival. 2. Need for airway support on arrival. (Airway support on arrival meeting exclusion criteria will include immediate need for high flow nasal cannula therapy, non-invasive CPAP/bi-PAP ventilation or invasive ventilation with endotracheal intubation, as decided by the attending Emergency Department (ED) physician. Supplemental oxygen therapy will not represent an exclusion criterion.) 3. Known renal, chronic pulmonary, neurologic, cardiac or systemic disease: these may influence outcomes after Mg. 4. Known hypersensitivity to Mg sulfate. 5. Previous enrollment. 6. Poor mastery of English and/or French language precluding informed consent understanding. 7. No phone/email; unavailable for follow-up

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute asthma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute asthma asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Asthma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    6 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Alberta Children's Hospital

    NOT_YET_RECRUITING

    Calgary, Alberta, T3B 6A8, Canada

  • CHU-Sainte Justine Hospital

    NOT_YET_RECRUITING

    Montreal, Quebec, H3T 1C5, Canada

  • Children's Hospital of Eastern Ontario

    NOT_YET_RECRUITING

    Ottawa, Ontario, K1H 8L1, Canada

  • McMaster Children's Hospital

    NOT_YET_RECRUITING

    Hamilton, Ontario, L8S 4L8, Canada

  • Stollery Children's Hospital

    NOT_YET_RECRUITING

    Edmonton, Ontario, T6G 2B7, Canada

  • The Hospital for Sick Children

    RECRUITING

    Toronto, Ontario, M5G 1X8, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.